Gene Biotherapeutics, Inc. filed its 10-K on May 22, 2015 for the period ending Dec 31, 2014. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 64 | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- CRXM Stock
- News Gene Biotherapeutics, Inc.
- Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt